EGFR and lung carcinoma: Our data provide rationale and a model for addressing early TKI responses in lung cancer, as well as raises the paradigm of how immediate-early tumor responses to EGFR-TKIs in “pre-clinical” in vivo models predicts long term therapy response in human lung adenocarcinoma.